CEO Chandler Robinson was paid $10,637,821 in fiscal year 2025, ↑ up 829.5% from fiscal year 2024 (SEC filing 0001437749-26-014183 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$10,637,821 ↑ Chandler Robinson total, FY2025 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | 87.81% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
MNPR's next annual pay disclosure, estimated April 30, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Chandler Robinson | $700,000 | $550,000 | $6,263,958 | $2,703,862 | $420,000 | $0 | $0 | $10,637,821 |
| Chief Executive Officer and Director | ||||||||
| Andrew Cittadine | 440,000 | 325,000 | 2,343,427 | 1,378,004 | 220,000 | 0 | 0 | 4,706,431 |
| Chief Operating Officer | ||||||||
| Quan Vu | 305,000 | 100,000 | 746,186 | 795,061 | 137,250 | 0 | 17,816 | 2,101,314 |
| Chief Financial Officer, Secretary, and Treasurer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Chandler Robinson | $10,637,821 | $1,144,480 | $1,778,667 | ↑ +9,493,341 |
| Andrew Cittadine | 4,706,431 | 554,796 | 911,161 | ↑ +4,151,635 |
| Quan Vu | 2,101,314 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Monopar Therapeutics's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper MNPR reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
The list of companies that name MNPR as a peer is temporarily unavailable — recheck shortly.
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| Andrew Cittadine | COO | $4,706,431 |
| Chandler Robinson | CEO | $10,637,821 |
| Quan Vu | CFO | $2,101,314 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Arthur J. Klausner | Independent Director | $401,224 |
| Christopher M. Starr, Ph.D | Chair of the Board | $536,724 |
| Kim R. Tsuchimoto | Independent Director | $389,937 |
| Lavina Talukdar | Independent Director | $225,331 |
| Michael J. Brown | Former director (through FY2025) | $77,457 |
| Raymond W. Anderson | Independent Director | $409,224 |
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Andrew Cittadine | Option | 3,021 | 3.07 | — |
| Chandler Robinson | Option | 11,092 | 15.8 | — |
| Chandler Robinson | Option | 59,334 | 31.7 | — |
| Chandler Robinson | RSU | 113,007 | — | 7,379,357 |
| Andrew Cittadine | RSU | 48,266 | — | 3,151,770 |
| Quan Vu | RSU | 9,826 | — | 641,638 |
| Chandler Robinson | Option | 16,735 | 75.94 | — |
| Quan Vu | Option | 7,135 | 75.94 | — |
| Quan Vu | Option | 20,312 | 30.93 | — |
| Andrew Cittadine | Option | 8,969 | 75.94 | — |
| Andrew Cittadine | Option | 32,584 | 31.7 | — |
| Andrew Cittadine | Option | 5,135 | 15.8 | — |
The Company's executive compensation program is designed to attract and retain talented executives and align their interests with those of stockholders by incentivizing the accomplishment of company goals.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-22 | 4,355,628 | 604,858 | 651 | 87.81% | Passed |
| 2025 | 2025-06-17 | 4,382,795 | 2,933 | 6,840 | 99.93% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-22 | 87.81%a |
| 2025 | 2025-06-17 | 99.93%b |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Christopher M. Starr, Ph.DIndependent · Board Chair · Plan Administrator | $80,000 | $0 | $336,724 | — | $120,000 | $536,724 |
| Raymond W. AndersonIndependent · Audit (Chair) · Compensation (Chair) · Plan Administrator · Nominating/Governance | 72,500 | 0 | 336,724 | — | 0 | 409,224 |
| Arthur J. KlausnerIndependent · Audit · Nominating/Governance (Chair) · Compensation · Not standing for re-election | 64,500 | 0 | 336,724 | — | 0 | 401,224 |
| Kim R. TsuchimotoIndependent | 40,000 | 0 | 336,724 | — | 13,213 | 389,937 |
| Lavina TalukdarIndependent · Audit · Nominating/Governance · Compensation · Plan Administrator | 53,039 | 0 | 172,292 | — | 0 | 225,331 |
| Michael J. BrownIndependent · Departed during FY | 31,000 | 0 | 46,457 | — | 0 | 77,457 |
| Chandler D. Robinson, MDEmployee director | — | — | — | — | — | 0 |
| Nicole SweenyIndependent · Nominating/Governance · Newly elected | — | — | — | — | — | — |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 12,500 / 7,500 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $341,039 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $133,213 |
| Total cost of the board | $474,252 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Monopar Therapeutics | 2025 | Chandler Robinson | $700,000 | $6,263,958 | $2,703,862 | $420,000 | $10,637,821 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Chandler Robinson | DEF 14A | 2026-04-30 | 0001437749-26-014183 | Section “Summary Compensation Table” · page 17. As printed: 10,637,821. Filing ↗machine: r1 · c28 · span 321786–321796 |
| 2 | Section 01, Andrew Cittadine | DEF 14A | 2026-04-30 | 0001437749-26-014183 | Section “Summary Compensation Table” · page 17. As printed: 4,706,431. Filing ↗machine: r7 · c28 · span 346733–346742 |
| 3 | Section 01, Quan Vu | DEF 14A | 2026-04-30 | 0001437749-26-014183 | Section “Summary Compensation Table” · page 17. As printed: 2,101,314. Filing ↗machine: r4 · c28 · span 334313–334322 |
| 4 | Section 07, pay ratio | 10-K/A | 2026-04-01 | 0001437749-26-010841 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 5 | Section 08, Christopher M. Starr, Ph.D | DEF 14A | 2026-04-30 | 0001437749-26-014183 | Section “Director Compensation”. As printed: 536,724. Filing ↗machine: span 243917–243924 |
| 6 | Section 08, Raymond W. Anderson | DEF 14A | 2026-04-30 | 0001437749-26-014183 | Section “Director Compensation”. As printed: 409,224. Filing ↗machine: span 250014–250021 |
| 7 | Section 08, Arthur J. Klausner | DEF 14A | 2026-04-30 | 0001437749-26-014183 | Section “Director Compensation”. As printed: 401,224. Filing ↗machine: span 253062–253069 |
| 8 | Section 08, Kim R. Tsuchimoto | DEF 14A | 2026-04-30 | 0001437749-26-014183 | Section “Director Compensation”. As printed: 389,937. Filing ↗machine: span 256114–256121 |
| 9 | Section 08, Lavina Talukdar | DEF 14A | 2026-04-30 | 0001437749-26-014183 | Section “Director Compensation”. As printed: 225,331. Filing ↗machine: span 258955–259028 |
| 10 | Section 08, Michael J. Brown | DEF 14A | 2026-04-30 | 0001437749-26-014183 | Section “Director Compensation”. As printed: 77,457. Filing ↗machine: span 246966–246972 |
| 11 | Section 08, Chandler D. Robinson, MD | DEF 14A | 2026-04-30 | 0001437749-26-014183 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 12 | Section 08, Nicole Sweeny | DEF 14A | 2026-04-30 | 0001437749-26-014183 | Section “Director Compensation”. As printed: —. Filing ↗ |
| 13 | Section 06, 2026 vote | Form 8-K | 2026-06-23 | 0001437749-26-021350 | Item 5.07 · say-on-pay result. As reported: 87.81% (votes for as printed: 4,355,628). Filing ↗ |
| 14 | Section 06, 2025 vote | Form 8-K | 2025-06-23 | 0001437749-25-020959 | Item 5.07 · say-on-pay result. As reported: 99.93% (votes for as printed: 4,382,795). Filing ↗ |
| 15 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 16 | Section 09b board cost (computed) | Computed | — | — | Cash 341,039 + equity 0 + all other 133,213 = 474,252, summed across the director compensation table rows.machine: formula: Σ = 474,252 |
| 17 | Monopar Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-30 | 0001437749-26-014183 | CEO total compensation as printed in Monopar Therapeutics's own proxy. As printed: 10,637,821. Filing ↗machine: r1 · c28 · span 321786–321796 |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.